The study aims to see if using Patient Derived Organoids (PDO) helps in choosing a suitable drug for treating pancreatic cancer patients. PDOs are tiny 3D models made from a patient's tumor tissues, grown in a lab. They are used to test which drugs might work best for treating the cancer. Researchers will review each participant's PDO drug results from earlier studies to identify the most effective drug, which will then be offered to the participant during the study.
- The study is for adults aged 18 and over with advanced pancreatic cancer.
- Participants must be able to take oral medication and agree to use contraceptives.
- Exclusions include ongoing severe side effects from previous treatments, significant heart issues, and certain other health conditions.
How understandable was the trial content above?
Hard to understand
Easy to understand